British Journal of Haematology | Wiley Online Library
Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma | Haematologica
VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma | 2 Minute Medicine
Treatment of Relapsed/Refractory Multiple Myeloma with Bendamustine, Bortezomib and Dexamethasone | Research To Practice
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma | Published in Journal of Health Economics and Outcomes Research
Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma | Haematologica
BOSTON trial (SVd) Update at ASCO 2020 | Int Myeloma Fn
VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma | 2 Minute Medicine
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma | Haematologica
Changes in hemoglobin and IgA levels. BDR: bortezomib, dexamethasone,... | Download Scientific Diagram
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study - ScienceDirect
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
British Journal of Haematology | Wiley Online Library
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
DREAMM Clinical Trial Program
BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma
The Lancet on X: "NEW—First large randomised phase 3 trial (BOSTON) finds regimen of selinexor, bortezomib & dexamethasone was associated with significant increase in progression-free survival vs bortezomib & dexamethasone in patients
Relapsed: D + VD Treatment | DARZALEX® IV (daratumumab)
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD - CDCN
Cancers | Free Full-Text | Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Phase I/II Trial of Panobinostat with Lenalidomide/Bortezomib/ Dexamethasone for Transplant-Eligible Patients with Newly Diagnosed MM | Research To Practice
Overall survival in patients receiving bortezomib or dexamethasone with... | Download Scientific Diagram
